louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05979220: Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
Official title: A Multicenter, Single Arm, Prospective Phase II Clinical Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Breast Cancer
Lead sponsor: West China Hospital
Sponsor class: OTHER
First posted: 2023-08-07
Enrollment: 178
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aimed to evaluate the efficacy and safety of Dalpiciclib combined with Letrozole in the maintenance treatment of HR positive and HER2 negative metastatic breast cancer after first-line chemotherapy.


Eligibility criteria: Inclusion Criteria:

1. Has the pathologically-confirmed diagnosis of locally recurrent or metastatic, hormone-receptor positive, HER2 negative Breast Cancer.
2. Age: 18 - 75 years old
3. Eastern Cooperative Oncology Group performance status (ECOG PS)=0\~1
4. Functions of liver and kidney is normal
5. Agreed to take contraceptive measures during treatment

Exclusion Criteria:

1. Confirmed diagnosis of HER2 positive disease.
2. Central nervous system metastasis
3. Patients who received prior treatment with any CDK4/6 inhibitor.
4. Clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class \> 2), or ventricular arrhythmia which need medical intervention；
5. Researchers believe that is not suitable for the study

Primary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: Estimated up to 23 months
Secondary outcomes:
measure: Progression Free Survival 2(PFS2)
timeFrame: Estimated up to 27-31 months
Other outcomes:
measure: Overall Survival(OS)
timeFrame: Estimated up to 5 years
measure: Objective Response Rate（ORR）
timeFrame: Estimated up to 23 months
measure: Clinical Benefit Rate (CBR)
timeFrame: Estimated up to 23 months
measure: Disease Control Rate (DCR)
timeFrame: Estimated up to 23 months
measure: Patient Reported Outcome (PRO)
timeFrame: Estimated up to 5 years
measure: Adverse events (AEs)
timeFrame: Estimated up to 5 years
Locations:
city: Chengdu
country: China
facility: West China Hospital, Sichuan University
state: Sichuan
Study officials:
References:
Clinical trial NCT03662620: Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers
Official title: A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypertension
Lead sponsor: Yuhan Corporation
Sponsor class: INDUSTRY
First posted: 2018-09-07
Enrollment: 67
Sex: MALE
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized, open-label, single-dose, 2-treatment, 2-sequence, 4-period replicate crossover design
Primary purpose: TREATMENT

Brief summary: This is a phase 1, randomized, open label, single-dose, replicate crossover clinical trial to compare the safety and pharmacokinetics of YH22162 in healthy male volunteers.

Hypothesis: Study drug and comparator drug are showing equal pharmacokinetics.

Detailed description: In ARM1, 32 subjects will be assigned and the subjects will be administered "comparator drug" at Day1/Day43 and "study drug" at Day22/64.

In ARM2, 32 subjects will be assigned and the subjects will be administered "study drug" at Day1/Day43 and "comparator drug" at Day22/64.

Eligibility criteria: Inclusion Criteria:

* Healthy male with body mass index(BMI) between 18.5 and 30 kg/m2
* Who has not suffered from clinically significant disease
* Provision of signed written informed consent

Exclusion Criteria:

* History of and clinically significant disease
* Administration of other investigational products within 3 months prior to the first dosing
* Volunteers considered not eligible for the clinical trial by the investigator due to reasons including laboratory test results, ECGs, or vital signs

Primary outcomes:
measure: AUClast of Telmisartan/amlodipine/chlorthalidone
timeFrame: 0-168 hrs
measure: Cmax of Telmisartan/amlodipine/chlorthalidone
timeFrame: 0-168 hrs
Secondary outcomes:
measure: AUCinf of Telmisartan/amlodipine/chlorthalidone
timeFrame: 0-168 hrs
measure: Tmax of Telmisartan/amlodipine/chlorthalidone
timeFrame: 0-168 hrs
measure: t1/2 of Telmisartan/amlodipine/chlorthalidone
timeFrame: 0-168 hrs
Other outcomes:
Locations:
city: Jeonju
country: Korea, Republic of
facility: Chonbuk National University Hospital
state: Jeollanam-do
Study officials:
affiliation: Chonbuk National University Hospital
name: Mingul Kim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02127320: Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe
Official title: A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2014-04-30
Enrollment: 24
Sex: MALE
Minimum age (years): 19
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the pharmacokinetic drug interactions between Rosuvastatin and Ezetimibe in Healthy Male Subjects


Eligibility criteria: Inclusion Criteria:

* Healthy male volunteer, age 19\~45 years
* The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 28 kg/m2
* Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial.

Exclusion Criteria:

* Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study
* History of relevant drug allergies or clinically significant hypersensitivity reaction.

Primary outcomes:
measure: Rosuvastatin AUCτ,ss
timeFrame: 1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h
measure: Rosuvastatin Cmax,ss
timeFrame: 1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h
measure: Ezetimibe Cmax,ss
timeFrame: 1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h
measure: Ezetimibe AUCτ,ss
timeFrame: 1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h
Secondary outcomes:
measure: Rosuvastatin Tmax,ss
timeFrame: 1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h
measure: Rosuvastatin t1/2β
timeFrame: 1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h
measure: Ezetimibe Tmax,ss
timeFrame: 1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h
measure: Ezetimibe t1/2β
timeFrame: 1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h
Other outcomes:
Locations:
city: Seoul, Korea, Republic of
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Hyeong-Seok Lim, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00094120: MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)
Official title: Safety and Efficacy of MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Macular Degeneration
Keywords: Age-Related Macular Degeneration - Wet Type
Lead sponsor: Genaera Corporation
Sponsor class: INDUSTRY
First posted: 2004-10-14
Enrollment: 60
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Age-Related Macular Degeneration (AMD) is a degenerative disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula.

Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine when administered with verteporfin therapy in patients with "wet" AMD.


Eligibility criteria: Inclusion Criteria:

* Patients with a diagnosis of "wet" age-related macular degeneration

Exclusion Criteria:

* Prior treatment for "wet" age-related macular degeneration

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Plymouth Meeting
country: United States
facility: Genaera Corporation
state: Pennsylvania
Study officials:
References:
Clinical trial NCT03426020: The Effect of Premedication Type(Pharmalogical and Non Pharmalogical) on Delirium
Official title: The Effect of Three Different Interventions on the Recovery Agitation and Delirium in the Pacu Pediatric Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Emergence Agitation
Keywords: Premedication
Pediatric patients
Emergence agitation
Lead sponsor: Diskapi Yildirim Beyazit Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2018-02-08
Enrollment: 90
Sex: ALL
Minimum age (years): 2
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Effect of pharmacologic or nonpharmacologic premedication on emergency agitation
Primary purpose: OTHER

Brief summary: Compare the effects of pharmacologic and nonpharmacologic premedications on postoperative emergence delirium and preoperative anxiety, vital parameters, blood pressure, heart rate, SpO2, and pain at PACU 15 minutes after adenotonsillectomy .

Detailed description: Compare the effects of

0.5 mg/kg oral midazolam,

watching film "Suko is being operated 'animation film (http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) and

playing a game named "fishing games" on postoperative emergency delirium by PAED (post anestesic emergency delirium) scale at PACU at arrive and every 5 minutes for 15 minutes after adenotonsillectomy.

Investigators also evaluated "Basic and 20 minutes after pharmacologic and nonpharmacolgic premedications on participitans anxiety by Modified Yale Preoperative Anxiety Scale m-YPAS scores"

Pain evaluated by FLACC (behoviaral pain assesment scale),at arrive and every 5 minutes for 15 minutes after adenotonsillectomy.

Blood pressure(mmHg), heart rate(beat/min) and SpO2(%) measured and recorded at arrive and every 5 minutes for 15 minutes after adenotonsillectomy.

Eligibility criteria: Inclusion Criteria:

* ASA I-II
* Pediatric patients
* Elective surgery
* Adenotonsillectomi

Exclusion Criteria:

* Cronicdesease
* Mental retarde
* Hearing and visual impaired
* Prematurite

Primary outcomes:
measure: Emergence agitation
timeFrame: Postoperative every 5 minutes for 15 minutes
Secondary outcomes:
measure: preoperative anxiety
timeFrame: 20 minutea after premedications.
measure: Post operative pain
timeFrame: Postoperative every 5 minutes for 15 minutes
measure: Mean arteriel pressure
timeFrame: Postoperative every 5 minutes for15 minutes
measure: Heart rate
timeFrame: Postoperative every 5 minutes for15 minutes.
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Reyhan Polat
Study officials:
References:
Clinical trial NCT04953520: Ultrasound-CT Fusion Image-guided Minimally Invasive Interventional Treatment of Lumbosacral Nerve Roots
Official title: Ultrasound-CT Fusion Image-guided Minimally Invasive Interventional Treatment of Lumbosacral Nerve Roots
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-08
Enrollment: 80
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is aimed at patients with low back and leg pain. The patients in the experimental group were guided by ultrasound-CT fusion imaging to insert the lumbar nerve root puncture needle.

Patients in the control group underwent the insertion of the lumbar nerve root puncture needle under the guidance of ultrasound alone.

Detailed description: A total of 80 patients with low back and leg pain were randomly divided into two groups, 30 people in each group. The patients in the experimental group were guided by ultrasound-CT fusion imaging to insert the lumbar nerve root puncture needle.Patients in the control group underwent the insertion of the lumbar nerve root puncture needle under the guidance of ultrasound alone.Follow-up of VAS pain score after lumbar nerve root block treatment. This study aims to establish a standardized operation method and process for lumbosacral nerve ultrasound-CT fusion guided interventional pain treatment.

Eligibility criteria: Inclusion Criteria:

1. Patients who need lumbar nerve root block treatment

Exclusion Criteria:

1. Tumor patients
2. Patients who have had lumbar spine surgery before

Primary outcomes:
measure: 1 month VAS pain score
timeFrame: VAS pain scores were performed 1 month after surgery
measure: 3 month VAS pain score
timeFrame: VAS pain scores were performed 3 month after surgery
measure: 6 month VAS pain score
timeFrame: VAS pain scores were performed 6 month after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Department of Ultrasound Diagnosis, Peking University Third Hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: Ligang Cui
role: STUDY_CHAIR
References:
Clinical trial NCT02356120: Inter-Observer Reliability and Accuracy of Tricuspid Annular Plane Systolic Excursion in Patients With Suspected PE in the ED
Official title: The Inter-observer Reliability and Diagnostic Accuracy of Tricuspid Annular Plane Systolic Excursion in Patients With Suspected Pulmonary Embolus in the Emergency Department
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Pulmonary Embolism
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2015-02-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The subject population will consist of a convenience sample, taken when study investigators are available, of all those patients for whom suspicion of PE is high enough that their attending physician has ordered a CTPA in the ED

Brief summary: The purpose of this study will be to evaluate the measurement of tricuspid annular plane systolic excursion (TAPSE) by emergency physician performed echocardiogram on patients with suspected pulmonary embolism (PE) who are scheduled to get a computed tomography of the pulmonary arteries (CTPA)

Detailed description: This will be a prospective observational cohort study aimed at determining the utility and reproducibility of TAPSE, in patients who present to the emergency department with suspected pulmonary embolism (PE). The gold standard diagnostic test for PE is computed tomography of the pulmonary arteries (CTPA). Any patient for whom a CTPA is ordered because of suspected PE is eligible for study inclusion

Eligibility criteria: Inclusion Criteria:

* Concern for PE by attending physician and CTPA ordered

Exclusion Criteria:

* If patient is under the age of 18, a prisoner, or a ward of the state
* CTPA ordered but not performed

Primary outcomes:
measure: Diagnostic Accuracy of TAPSE (The association of TAPSE measurements with a diagnosis of PE will be explored using multivariate analysis)
timeFrame: 0 days
Secondary outcomes:
measure: Inter-Observer Agreement (To assess the interobserver reproducibility of measuring TAPSE, intra-class correlation coefficients and Bland-Altman analysis will be performed.)
timeFrame: 0 days
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University
state: Connecticut
Study officials:
affiliation: Yale University
name: Chris Moore, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06374420: Small Airway Disease And Bronchial Hyperreactivity In Patients With Post Acute Covid-19 Syndrome
Official title: Small Airway Disease And Bronchial Hyperreactivity In Patients With Post Acute Covid-19 Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2024-04-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults with confirmed covid 19 who remaining symptomatic after 30 days from the diagnosis.

Brief summary: The aim of this work is to estimate the frequency of small airway disease and/or the bronchial hyperreactivity in follow up of postacute covid survivors.

Detailed description: This is a observational longitudinal study investigating pulmonary sequelae of covid-19.

Study site:

Mansoura university hospital, chest department and post covid outpatient clinic.

Elmahalla chest hospital and outpatients clinic.

Time of study :

Two years from September 2021 to September 2023

Target population:

Adults with confirmed covid 19 who remaining symptomatic after 30 days from the diagnosis.

Sample size The study will include 100 selected cases during period from 2021 to 2023

Patients :

The enrolled patients are adults who survived acute covid-19 and presented for clinical follow up.

Eligibility criteria: Inclusion Criteria:

* Ambulatory adult patients confirmed diagnosis of covid -19 either on typical CT chest basis or PCR and passed period of acute illness (28 days from start of symptoms) but still with clinical symptoms.

Exclusion Criteria:

* Hospitalized or requiring intensive care unit. Known patients with chronic lung diseases Uncontrolled comorbidities

Primary outcomes:
measure: investigating pulmonary sequelae of covid-19.
timeFrame: 3moth
measure: investigating pulmonary sequelae of covid-19.
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mansoura University
state: Dakhlia
Study officials:
References:
Clinical trial NCT06088420: Analgesic Efficacy of Different Nerve Blocks in Postoperative Cesarean Section
Official title: Analgesic Efficacy of Erector Spinae Block , Quadratus Lumborum Block, and Intrathecal Morphine for Postoperative Pain Relief After Cesarean Section: A Randomized Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Post Operative Pain
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-10-18
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: comparing analgesic efficacy of different nerve blocks on post operative cesarean sections.

Detailed description: Analgesic efficacy of Erector Spinae, Quadratus Lumborum and Intrathecal Morphine for post operative pain relief after cesarean section,

Eligibility criteria: Inclusion Criteria:

* 18-40 years old
* more or equal 37 weeks of gestation
* ASA 1,2
* Elective cesarean delivery

Exclusion Criteria:

* Patient refusal
* inability to cooperate with or understand the study
* local infection.
* bleeding disorder
* known anaphylaxis to any drug used in the trial
* ASA physical status more than 2
* emergency operations
* chronic opioid use (opioid use in the past 3 months)
* Neurologic deficit or disorder
* contraindication to regional anesthesia.

Primary outcomes:
measure: Duration of analgesia until first analgesic request.
timeFrame: 24 hours .
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Mahmoud Mamdouh Ekram
state: Manfalout
Study officials:
References:
Clinical trial NCT03400020: Efficacy of Vitamin C Administration for the Prevention of Postpolypectomy Bleeding
Official title: Efficacy of Vitamin C Administration for the Prevention of Postpolypectomy Bleeding
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postpolypectomy Bleeding
Lead sponsor: Ilam University of Medical Sciences
Sponsor class: OTHER
First posted: 2018-01-17
Enrollment: 156
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Postpolypectomy bleeding is the most common major complication following a colonoscopic polypectomy procedure. The incidence rate ranging from 0.3 to 6.1%. Several preventive methods such as detachable snare and adrenaline injection have been proposed in the management of postpolypectomy bleeding in large colonic polyps. It has been demonstrated that administration of ascorbic acid (vitamin C) in abdominal surgeries could reduce the blood loss during the procedure, operation time and days of hospitalization. So the investigators designed a prospective, randomized study to compares the efficacy of vitamin C administration with application of prophylactic clip and detachable snare in the prevention of postpolypectomy bleeding in large polyps.

Detailed description: In this prospective, randomized clinical trial, patients diagnosed with colon polyps with a diameter \> 10 mm will randomized to receive either a 500 mg vitamin C in normal saline injection or a normal saline injection 2 hours before polypectomy. This administration will continued for 3 days after polypectomoy. Postpolypectomy bleeding is defined either as (1) early: occurring either during an endoscopic procedure or immediately after as hematochezia within 24 h or (2) delayed: any bleeding event that occurring between day 2 and day 30 following the polypectomy procedure.

Eligibility criteria: Inclusion Criteria:

* Colorectal polyps larger than 10 mm.

Exclusion Criteria:

bleeding tendency poor preparation

Primary outcomes:
measure: Early postpolypectomy bleeding
timeFrame: up to 24 hours
measure: Late postpolypectomy bleeding
timeFrame: between day 2 and day 30
Secondary outcomes:
Other outcomes:
Locations:
city: Ilam
country: Iran, Islamic Republic of
facility: Mostafa Khomaini Hospital
Study officials:
affiliation: Ilam University of Medical Sciences
name: Shaahin Shahbazi, MD
role: STUDY_CHAIR
References: